Table 2 Completed targeted therapy clinical trials in ES-SCLC
Phase | Study | Treatment arms | Patients (n) | ORR (%) | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|
First line | ||||||
 II | ECOG-ACRIN 2511 | Veliparib + etoposide + cisplatin vs. placebo + etoposide + cisplatin | 128 | 71.9 vs. 65.6 (P = 0.57) | 6.1 vs. 5.5 (HR = 0.75; P = 0.06) | 10.3 vs. 8.9 (HR = 0.83; P = 0.17) |
Relapsed | ||||||
 II | NCT01638546 | Veliparib + temozolomide vs.placebo + temozolomide | 104 | 39 vs. 14 (P = 0.016) | 3.8 vs. 2.0 (P = 0.39) | 8.2 vs. 7.0 (P = 0.50) |
 II | NCT02454972 | Lurbinectedin (PM01183) | 68 | 39.3 | 4.1 | 11.8 |
 II | TRINITY | Rovalpituzumab tesirine | 177 | 16 | 4.1a | 5.6 |
 II | ALTER 1202 | Anlotinib vs. placebo | 120 | 71.6 vs. 13.2b | 4.1 vs. 0.7 (HR = 0.19; P < 0.0001) | 7.3 vs. 4.9 (HR = 0.53; P = 0.0210, not yet mature) |